74 FR 229 pgs. 62793-62795 - Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability
Type: NOTICEVolume: 74Number: 229Pages: 62793 - 62795
Docket number: [Docket No. FDA-2007-D-0369] (formerly Docket No. 2007D-0168)
FR document: [FR Doc. E9-28593 Filed 11-30-09; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2007-D-0369] (formerly Docket No. 2007D-0168)
Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA) is announcing the availability of additional draft and revised draft product-specific bioequivalence (BE) recommendations. The recommendations provide product-specific guidance on the design of BE studies to support abbreviated new drug applications (ANDAs). In the Federal Register of May 31, 2007, FDA announced the availability of a draft guidance for industry entitled "Bioequivalence Recommendations for Specific Products," explaining the process that would be used to make product-specific BE recommendations available to the public on FDA's Web site. The BE recommendations identified in this notice were developed using the process described in that guidance.
DATES:
Submit written or electronic comments on the draft and revised draft product-specific BE recommendations listed in this notice by February 1, 2010.
ADDRESSES:
Submit written requests for single copies of the individual BE guidances to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the draft product-specific BE recommendations to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov . See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance recommendations.
FOR FURTHER INFORMATION CONTACT:
Doan T. Nguyen, Center for Drug Evaluation and Research (HFD-600), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9314.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of May 31, 2007 (72 FR 30388), FDA announced the availability of a draft guidance for industry entitled "Bioequivalence Recommendations for Specific Products," that explained the process that would be used to make product-specific BE recommendations available to the public on FDA's Web site at http://www.fda.gov/CDER/GUIDANCE/bioequivalence/default.htm . As described in that draft guidance, FDA adopted this process as a means to develop and disseminate product-specific BE recommendations and provide a meaningful opportunity for the public to consider and comment on those recommendations. Under that process, draft recommendations are posted on FDA's Web site and announced periodically in the Federal Register . The public is encouraged to submit comments on those recommendations within 60 days of their announcement in the Federal Register . FDA considers any comments received and either publishes final recommendations, or publishes revised draft recommendations for comment. Recommendations were last announced in the Federal Register of June 8, 2009 (74 FR 27146). This notice announces draft product-specific recommendations, either new or revised, that have been posted on FDA's Web site in the period from November 1, 2008, through December 1, 2009.
II. Drug Products for Which New Draft Product-Specific BE Recommendations Are Available
FDA is announcing draft BE product-specific recommendations for drug products containing the following active ingredients:
| A | |
| Adapalene (multiple reference listed drugs (RLDs)) | |
| Adapalene; Benzoyl Peroxide | |
| Alendronate Sodium; Cholecalciferol | |
| Aliskiren Hemifumarate | |
| Aliskiren Hemifumarate; Hydrochlorothiazide | |
| Allopurinol | |
| Ambrisentan | |
| Amlodipine Besylate; Atorvastatin Calcium | |
| Atenolol | |
| B | |
| Bromfenac Sodium | |
| Bromocriptine | |
| Budesonide | |
| C | |
| Calcium Acetate | |
| Cephalexin | |
| Chlorpheniramine Polistirex; Hydrocodone Polistirex | |
| Ciprofloxacin | |
| Clonidine | |
| Clotrimazole (multiple RLDs) | |
| D | |
| Desmopressin Acetate | |
| Desogestrel; Ethinyl Estradiol (multiple RLDs) | |
| Desvenlafaxine Succinate | |
| Dextroamphetamine Sulfate | |
| Dextromethorphan Hydrobromide; Guaifenesin | |
| Diclofenac Sodium (multiple RLDs) | |
| Doxycycline Hyclate | |
| Drospirenone; Ethinyl Estradiol | |
| E | |
| Eletriptan Hydrobromide | |
| Estradiol (multiple RLDs) | |
| Ethinyl Estradiol; Levonorgestrel (multiple RLDs) | |
| Ethinyl Estradiol; Norelgestromin | |
| Ethinyl Estradiol; Norethindrone Acetate (multiple RLDs) | |
| Ethinyl Estradiol; Norgestrel (multiple RLDs) | |
| F | |
| Famotidine | |
| Felodipine | |
| Fenoprofen Calcium | |
| Fentanyl | |
| Fexofenadine HCl | |
| Fexofenadine; Pseudoephedrine (multiple RLDs) | |
| Fludrocortisone Acetate | |
| G | |
| Glimepiride; Pioglitazone HCl | |
| Glycopyrrolate | |
| Guaifenesin; Pseudoephedrine HCl | |
| H | |
| Haloperidol | |
| Hydrocodone Bitartrate; Acetaminophen | |
| Hydroxyzine Pamoate (multiple RLDs) | |
| I | |
| Imatinib Mesylate | |
| L | |
| Lansoprazole | |
| Levetiracetam | |
| Linezolid | |
| Loratadine | |
| M | |
| Meprobamate | |
| Metformin HCl (multiple RLDs) | |
| Metformin HCl; Repaglinide | |
| Methotrexate Sodium (multiple RLDs) | |
| Metoclopramide HCl | |
| Miconazole Nitrate (multiple RLDs) | |
| Mycophenolic Acid | |
| N | |
| Nadolol | |
| Naltrexone | |
| Niacin | |
| Nifedipine | |
| Nilutamide | |
| Nisoldipine | |
| Nitazoxanide | |
| Nitrofurantoin | |
| Nitrofurantoin Macrocrystalline | |
| Norethindrone | |
| Norethindrone Acetate | |
| O | |
| Oxybutynin Chloride | |
| P | |
| Phendimetrazine Tartrate (multiple RLDs) | |
| Phentermine HCl (multiple RLDs) | |
| Phytonadione | |
| Pramipexole Dihydrochloride | |
| Prednisolone | |
| Pregabalin | |
| Propafenone HCl | |
| Pyridostigmine Bromide | |
| R | |
| Raltegravir Potassium | |
| Ramelteon | |
| Raniditine (multiple RLDs) | |
| Rasagiline Mesylate | |
| Rivastigmine Tartrate | |
| S | |
| Scopolamine | |
| Selegiline | |
| Sodium Phenylbutyrate (multiple RLDs) | |
| Sorafenib Tosylate | |
| T | |
| Tamoxifen Citrate | |
| Telbivudine | |
| Temazepam | |
| Terbinafine HCl | |
| Toremifene Citrate | |
| Trandolapril; Verapamil HCl | |
| Triamcinolone Acetonide (multiple RLDs) | |
| V | |
| Voriconazole | |
| Z | |
| Zolpidem |
III. Drug Products for Which Revised Draft Product-Specific BE Recommendations Are Available
FDA is announcing revised draft BE product-specific recommendations for drug products containing the following active ingredients. These recommendations were previously posted on FDA's Web site:
| A | |
| Azacitidine | |
| B | |
| Busulfan | |
| C | |
| Carbidopa; Entacapone; Levodopa | |
| D | |
| Darunavir Ethanolate | |
| Desogestrel; Ethinyl Estradiol | |
| Doxercalciferol | |
| E | |
| Ethinyl Estradiol; Norethindrone (multiple RLDs) | |
| F | |
| Fluoxetine HCl; Olanzapine | |
| H | |
| Hydrochlorothiazide; Lisinopril | |
| I | |
| Ibuprofen | |
| L | |
| Lansoprazole | |
| Lovastatin; Niacin | |
| M | |
| Methylprednisolone Acetate | |
| Melphalan | |
| N | |
| Nabilone | |
| O | |
| Omeprazole; Sodium Bicarbonate | |
| Q | |
| Quetiapine Fumarate | |
| R | |
| Risedronate Sodium | |
| S | |
| Sevelamer Carbonate | |
| Sevelamer HCl | |
| Sildenafil Citrate | |
| T | |
| Temozolomide | |
| Topiramate | |
| Tacrolimus |
For a complete history of previously published Federal Register notices, please go to http://www.regulations.gov and enter docket number FDA-2007-D-0369.
These guidances are being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidances represent the agency's current thinking on product-specific design of BE studies to support ANDAs. They do not create or confer any rights for or on any person and do not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.
IV. Comments
Interested persons may submit to the Division of Dockets Management (see ADDRESSES ) written or electronic comments on any of the specific BE recommendations posted on FDA's Web site. Submit a single copy of electronic comments or two paper copies of mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The guidance, notices, and received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
V. Electronic Access
Persons with access to the Internet may obtain the document at either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http://www.regulations.gov .
Dated: November 20, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-28593 Filed 11-30-09; 8:45 am]
BILLING CODE 4160-01-S